News Releases

August 8, 2018
Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates
- Data from Phase 1/2 studies of SYNB1618 and SYNB1020 expected by end of 2018 – – On track to advance first immuno-oncology program into IND-enabling studies in fourth quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Synlogic, Inc....
August 7, 2018
Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the 2018 Wedbush PacGrow Healthcare Conference at

...
June 25, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

- Data highlight broad capabilities of Synlogic’s Synthetic Biotic platform to generate candidates for the potential treatment of cancer – - First program advancing into IND-enabling studies in 2H2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a

...
June 25, 2018
Synlogic Joins Russell 3000® Index

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company’s addition to the Russell 3000® Index, following the Russell US Indices’ annual

...
June 11, 2018
Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

– SYNB1618 currently being evaluated in a Phase 1/2a clinical trial in healthy volunteers and patients with Phenylketonuria (PKU); interim data expected in 2H 2018 – – Data presented in plenary session at ASM Microbe 2018 demonstrate lowering of blood phenylalanine (Phe) levels in an animal model

...
June 4, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®
– SYNB1020 currently being evaluated in a Phase 1b/2a clinical trial in patients with elevated ammonia due to cirrhosis; topline data expected by YE2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a clinical-stage drug discovery and development company...
May 15, 2018
Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update

– Treated first subject in clinical trials of two Synthetic Biotic TM medicines, SYNB1020 and SYNB1618; both studies expected to generate data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to

...
May 10, 2018
Synlogic Announces Leadership Change

– Jose Carlos Gutiérrez- Ramos resigns as Synlogic’s President and Chief Executive Officer and member of its board of directors – – Aoife Brennan , current Synlogic Chief Medical Officer, named Interim President and Chief Executive Officer – CAMBRIDGE, Mass.

...
April 25, 2018
Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria

– Phase 1/2a clinical study of SYNB1618 evaluating safety and tolerability as well as exploratory endpoints expected to report interim data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage company applying synthetic biology to probiotic

...
April 18, 2018
Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria

– Second Synthetic Biotic™ program to move into clinical studies in 2018 – – SAD/MAD study will include healthy volunteers and expansion cohorts of adult patients with PKU – – Interim data expected in 2018; full data in 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.

...
April 16, 2018
Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting

– Data highlight the application of Synthetic Biotic medicines for the potential treatment of a variety of solid tumors – – Company is advancing the first candidate from this program into IND-enabling studies in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.

...
April 6, 2018
Synlogic Announces Registered Direct Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2018-- Synlogic, Inc. (Nasdaq: SYBX) , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual fund investor in

...
Displaying 61 - 72 of 115